Navigation Links
Cancer biomarker -- detectable by blood test -- could improve prostate cancer detection

CINCINNATIA new study supports the use of a DNA-based "biomarker" blood test as a complement to the prostate-specific antigen (PSA) test currently offered to screen men for prostate cancer. University of Cincinnati (UC) researchers report their findings online ahead of print in the British Journal of Cancer.

Researchers conducted a meta-analysis of existing published data related to DNA methylation in bodily fluids. The goal was to evaluate a specific cancer biomarkerknown as GSTP1as a screening tool for prostate cancer.

The study was a cross-disciplinary collaborative effort of UC molecular epidemiologist Tianying Wu, MD, PhD, epigenetic expert and UC environmental health chair Shuk-Mei Ho, PhD, former UC environmental health post-doc Wang-Yee Tang, PhD, UC statistician Jeff Welge and Harvard cancer epidemiologist Edward Giovannucci, MD. Wu's postdoctoral fellow Palash Mallick, PhD, also contributed to the study.

Wu merged epidemiologic and molecular data from 22 studies conducted in the United States and Europe between 2000 and 2009. More than 2000 human biologic samples (1,635 prostate cancer cases and 573 controls) were analyzed for the current study, including whole blood, plasma, urine, ejaculates and other secretions.

Wu determined that GSTP1 was a statistically significant biomarker for prostate cancer and could increase the specificity of prostate cancer diagnosis by up to 70 percent as compared to using the PSA test alone.

"The PSA test is highly sensitive, but it cannot differentiate between prostate cancer and benign prostatic conditions such as benign prostatic hyperplasia, leading many men to have unnecessary biopsies," says Wu, lead author of the study and assistant professor of environmental health at UC.

"It is unlikely that we would find a marker that has the same sensitivity as PSA," she adds, "but finding a highly specific circulating biomarker like GSTP1 that complements the PSA test could greatly improve the accuracy of prostate cancer detection before recommending patients for an invasive biopsy."

Alterations of the DNA methylation process are commonly associated with cancerous tumor growth and changes can be detected in bodily fluids. GSTP1 DNA methylation is particularly associated with prostate cancer and can be detected in the bloodstream using high throughput standardized molecular biology techniques

"Measuring GSTPI in plasma or urine is an easy and non-invasive test. This biomarker will give physicians reassurance regards to whether to conduct biopsies in selected patients," adds Wu.


Contact: Amanda Harper
University of Cincinnati Academic Health Center

Related biology news :

1. Breast cancer treatment resistance linked to signaling pathway
2. Jefferson scientists deliver toxic genes to effectively kill pancreatic cancer cells
3. The dietary supplement genistein can undermine breast cancer treatment
4. Saliva proteins could help detection of oral cancer
5. Vitamin C supplements may reduce benefit from wide range of anti-cancer drugs
6. Breakthrough optical technology to assess colon cancer risk, accuracy
7. Breast cancer cells recycle to escape death by hormonal therapy
8. Nanodiamond drug device could transform cancer treatment
9. Second lumpectomy for breast cancer reduces survival rates
10. Study looks at psychological impact of gene test for breast cancer
11. SNM releases new fact sheet on breast cancer and molecular imaging
Post Your Comments:
(Date:11/9/2015)... , Nov. 09, 2015 ... addition of the "Global Law Enforcement ... offering. --> ) has ... Law Enforcement Biometrics Market 2015-2019" report ... and Markets ( ) has announced ...
(Date:11/4/2015)... ALBANY, New York , November 4, 2015 /PRNewswire/ ... According to a new market report published by Transparency ... Size, Share, Growth, Trends and Forecast 2015 - 2022", ... value of US$ 30.3 bn by 2022. The market ... during the forecast period from 2015 to 2022. Rising ...
(Date:10/29/2015)... 29, 2015   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that it ... (MHTA) as one of only three finalists for a ... Small and Growing" category. The Tekne Awards honor ... superior technology innovation and leadership. iMedNet™ ...
Breaking Biology News(10 mins):
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... The Global Genomics Industry ... and in-depth study on the current state of ... ) , The report provides ... classifications, applications and industry chain structure. The Genomics ... including development trends, competitive landscape analysis, and key ...
(Date:11/24/2015)... , Nov. 24, 2015 Cepheid (NASDAQ: ... speaking at the following conference, and invited investors to ... NY      Tuesday, December 1, 2015 at 11.00 ... NY      Tuesday, December 1, 2015 at 11.00 ... Conference, New York, NY      Tuesday, ...
(Date:11/24/2015)... Tampa, Florida (PRWEB) , ... November 24, 2015 ... ... its biggest event of the year and one of the premier annual events ... USA, and ran from 8–11 November 2015, where ISPE hosted the largest number ...
Breaking Biology Technology: